Meeting
2018 ASCO Annual Meeting
Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study.
Authors
Alexios Matikas
Department of Oncology, Karolinska Institutet and University Hospital, Stockholm, Sweden
Alexios Matikas , Theodoros Foukakis , Volker Moebus , Richard Greil , Nils-Olof Bengtsson , Guenther G. Steger , Michael Untch , Hemming Johansson , Mats Hellstrom , Per Malmström , Michael Gnant , Sibylle Loibl , Jonas C. S. Bergh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT00798070
Citation
J Clin Oncol 36, 2018 (suppl; abstr 538)
DOI
10.1200/JCO.2018.36.15_suppl.538
Abstract #
538
Poster Bd #
30
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.
First Author: Theodoros Foukakis
First Author: Begoña Bermejo
Poster
2022 ASCO Annual Meeting
The real-world experience of adjuvant docetaxel and cyclophosphamide (TC) chemotherapy in HER-2 negative breast cancer.
First Author: Danilo Giffoni M. M. Mata
Poster
2017 ASCO Annual Meeting
Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).
First Author: Justin Stebbing